CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

16 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Dec 2024 20:44:38 By Nasdaq GlobeNewswire

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

09 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

15 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

14 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

12 Nov 2024 16:07:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

16 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Oct 2024 16:40:28 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

08 Oct 2024 23:55:11 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

08 Oct 2024 16:01:51 By Nasdaq GlobeNewswire

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

26 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2024 16:40:25 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

29 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

08 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

18 Jul 2024 16:05:00 By Nasdaq GlobeNewswire